MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma
Ankit Jain(The Royal Wolverhampton NHS Trust), Harsha Gowda(Signum Biosciences (United States))
Cited by 21
Related Papers
Differential proteomic analysis of synovial fluid from rheumatoid arthritis and osteoarthritis patients
|Clinical Proteomics|2014|173
Proteomic analysis of human osteoarthritis synovial fluid
|Clinical Proteomics|2014|149
A network map of Interleukin-10 signaling pathway
|Journal of Cell Communication and Signaling|2015|130
Proteomics of Human Aqueous Humor
|OMICS A Journal of Integrative Biology|2015|53
An integrated signal transduction network of macrophage migration inhibitory factor
|Journal of Cell Communication and Signaling|2016|39